Research
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
Scientific reports – July 17, 2024
Summary
Psilocybin-assisted psychotherapy shows promising results for cancer patients experiencing end-of-life distress. In a groundbreaking Canadian program, eight palliative care patients received legal access to psychedelics for therapeutic use. After treatment, participants reported significant improvements in anxiety, depression, pain, and quality of life. While most found the experience meaningful, careful screening remains vital.
Abstract
Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with lif...
Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports
Journal of Psychedelic Studies – July 17, 2024
Summary
Users of 5-MeO-DMT, a potent hallucinogen, strongly perceived a need for care. Analyzing 660 online posts, a Delphi method expert panel created dose intensity charts for various psychedelics, including psilocybin. While oral administration was common for lower doses, greater drug purity from chemical synthesis and alkaloids, and higher doses, correlated with a perceived need for support. This work, vital for Psychology and Psychedelics and Drug Studies, informs medicine, guiding future biochemical analysis of substances like mescaline.
Abstract
Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing bot...
Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report
Frontiers in Psychiatry – July 16, 2024
Summary
Strikingly, a single patient with major depressive disorder safely received the hallucinogen Psilocybin, an alkaloid often produced by chemical synthesis, alongside two serotonergic antidepressants, duloxetine and vortioxetine. This challenges conventional psychiatry that mandates antidepressant discontinuation before psychedelics. Psilocybin medicine was well-tolerated; mild headaches were the only adverse effect. However, discontinuing duloxetine worsened his anxiety, underscoring the vital neurotransmitter receptor influence on behavior. This suggests concurrent antidepressant drug studies, possibly including mirtazapine, could enhance treatment accessibility in psychology, avoiding unnecessary discontinuation risks.
Abstract
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interaction...
Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis
World Journal of Clinical Oncology – July 16, 2024
Summary
Profound anxiety relief emerges for advanced cancer patients undergoing psilocybin-assisted therapy. A meta-analysis of 7 studies, encompassing 132 participants, revealed substantial reductions in anxiety, with effect sizes of 35.15 at 4.5 months and 33.06 at 6.5 months. This medicine, a psychedelic alkaloid, also improved quality of life and pain control. Such findings are crucial for oncology and intensive care medicine, enriching diverse academic research themes in Psychedelics and Drug Studies.
Abstract
BACKGROUND Psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, is known for its effects on anxiety and de...
Inter-individual variability in neural response to low doses of LSD.
Translational psychiatry – July 15, 2024
Summary
Small doses of LSD affect people differently based on their baseline mental state. In a groundbreaking study, participants receiving micro-amounts of LSD showed increased alertness and attention, with effects strongest in those who initially had lower cognitive performance. Brain activity changes persisted for a week after treatment, suggesting lasting neural adaptations.
Abstract
The repeated use of small doses of psychedelics (also referred to as "microdosing") to facilitate benefits in mental health, cognition, and mood is...
Target analysis of psychoactive drugs in oral fluid by QuEChERS extraction and LC-MS/MS.
Journal of pharmaceutical and biomedical analysis – July 15, 2024
Summary
A breakthrough testing method reveals surprising insights into drug consumption at electronic dance music parties. Using advanced LC-MS/MS technology, researchers analyzed oral fluid samples from party attendees to detect over 70 substances. The method proved highly sensitive, identifying trace amounts of both traditional and new psychoactive substances. Results showed MDMA and cocaine were most common, but many participants were unaware of exactly what they'd consumed.
Abstract
This study aimed to validate a modified QuEChERS method, followed by liquid chromatography-tandem mass spectrometry, for the determination of 51 ps...
Long-term follow-up of participants in ketamine clinical trials for mood disorders.
Journal of affective disorders – July 15, 2024
Summary
Groundbreaking clinical trials at NIMH revealed promising long-term safety data for ketamine and esketamine in treating depression. Over 200 participants were followed for an average of 9 years, showing that those who initially received ketamine treatment were more likely to seek it again, with no signs of abuse or increased risk. The treatment proved both safe and effective for managing depression symptoms.
Abstract
Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a u...
Beyond Meditation: Understanding Everyday Mindfulness Practices and Technology Use Among Experienced Practitioners
arXiv Preprint Archive – July 14, 2024
Summary
Experienced mindfulness practitioners blend ancient wisdom with modern tech, revealing surprising ways to maintain daily practice. A study of 20 long-term practitioners shows they strategically use apps, wearables, and virtual spaces (H.5.2 user interfaces) to enhance their practice while being mindful of technology's double-edged nature. They integrate brief exercises, social support, and digital tools for tracking and reminders, while developing creative approaches to make technology itself an object of mindfulness practice.
Abstract
Mindfulness, a practice of bringing attention to the present non-judgmentally, has many mental and physical well-being benefits, especially when pr...
Esketamine in depression: putative biomarkers from clinical research.
European archives of psychiatry and clinical neuroscience – July 13, 2024
Summary
Breakthrough research reveals how esketamine offers new hope for treatment-resistant depression through unique brain mechanisms. Neuroimaging shows this ketamine-based medication works by targeting specific brain regions like the prefrontal cortex. Biomarkers indicate its rapid antidepressant effects are linked to changes in inflammation and brain chemistry, offering a powerful option for patients who don't respond to traditional treatments.
Abstract
The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for tr...
Nitric Oxide Donor Sodium Nitroprusside Reduces Racemic Ketamine-But Not Esketamine-Induced Pain Relief.
ACS pharmacology & translational science – July 12, 2024
Summary
A fascinating discovery shows that a common blood pressure medication can selectively block pain relief from one form of ketamine but not another. The medication, sodium nitroprusside, completely prevents pain relief from R-ketamine while leaving S-ketamine's pain-relieving properties intact. This finding helps explain how different forms of ketamine work in the body and could lead to more targeted pain treatments.
Abstract
The anesthetic, analgesic and antidepressant drug ketamine produces dissociation with symptoms of psychosis and anxiety, an effect attributed to ne...
Psychedelic experiences and long-term spiritual growth: a systematic review
Current Psychology – July 12, 2024
Summary
Psychedelics, including psilocybin, significantly foster long-term spiritual growth, a systematic Psychology review of 34 studies involving 19,724 participants reveals. These substances, often associated with profound religious experience and Mysticism, enhance feelings of unity and Transcendence, deepen spiritual Faith, and boost Social connectedness. Individuals report stronger divine connections, increased meaning, and greater engagement in Spirituality. This suggests a powerful link between certain Chemical synthesis and alkaloids and an individual's Religiosity and overall well-being, influencing their religious orientation.
Abstract
Abstract Psychedelic substances, which can occasion mystical experiences, are sometimes used for religious and spiritual reasons. Despite strong li...
Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)
Journal of Psychedelic Studies – July 12, 2024
Summary
Harnessing the therapeutic potential of psilocybin-induced mystical experiences in clinical psychology just got closer for Norwegian patients. A new tool, crucial for Psychedelics and Drug Studies, has been meticulously developed. Through rigorous translation, including cognitive debriefing with six experts and pilot testing on six psychedelic users, a Norwegian version of the Mystical Experience Questionnaire is now ready. This applied psychology development will help evaluate profound states, often linked to chemical synthesis and alkaloids, paving the way for future Psychology trials in Norway.
Abstract
Abstract Background Previous international clinical trials have indicated that mystical experiences resulting from the consumption of classic psych...
Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions
OpenAlex – July 12, 2024
Summary
Psilocybin, a hallucinogen from certain mushrooms, showed a remarkably low public health risk. Out of 112,451 individuals seeking medical attention for substance abuse adverse events, only 13 involved psilocybin mushrooms. While 46.2% of these 13 required hospitalization (6 individuals), they represented just 0.02% of all hospitalizations. Crucially, no fatalities were linked to psilocybin, unlike the 1.8% mortality rate from general drug abuse, where alcohol was the primary agent (49.2%). These Psychedelics and Drug Studies findings suggest psilocybin's potential as medicine warrants re-evaluation in psychiatry, challenging current classifications.
Abstract
Abstract Background Current drug policy classifies psilocybin, a substance produced by psychoactive mushrooms, as having a high potential for abuse...
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.
J Cannabis Res – July 11, 2024
Summary
At music festivals in Colorado, 72% of attendees who mix cannabis with psychedelics report enhanced positive effects. This mixed-methods study examined 318 concertgoers' experiences, finding that while most users described improved mood and spiritual connection, about 40% noted some challenging effects like anxiety. Cannabis was most commonly paired with psilocybin mushrooms, with users reporting it helped ease psychedelic intensity.
Abstract
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using ...
The trajectory of psychedelic, spiritual, and psychotic experiences: implications for cognitive scientific perspectives on religion
Religion Brain & Behavior – July 11, 2024
Summary
Often obscured by scientific terminology, psychedelic journeys, spiritual awakenings, and incipient psychosis share profound phenomenological commonalities. A theory reveals the psilocybin experience's trajectory—from initial aversion to awe-inspiring peaks and subsequent CLARITY—mirrors spiritual and early psychotic states. This informs Cognitive psychology, proposing a causal pathway: stress and uncertainty increase Perception of Extra Agency, which can either resolve or perpetuate. Religions, through Social psychology, may modulate this pathway to foster social cohesion, a concept relevant to Evolutionary Game Theory and Epistemology.
Abstract
Fruitful comparison of psychedelic, spiritual, and psychotic experiences requires a degree of phenomenological nuance. Some shared features of thes...
Client treatment preferences in psychedelic-assisted therapy for depression in participants with depressive symptoms
Journal of Psychedelic Studies – July 11, 2024
Summary
Who your therapist is can matter as much as the treatment itself. Research explored if people seeking psychedelic-assisted therapy or traditional talk therapy (CBT) prefer providers of the same gender or race. Over 600 participants rated these preferences. Findings reveal that racial, ethnic, and female participants highly value a same-gender therapist, especially in traditional talk therapy. A same-race therapist was highly valued by racial and ethnic minority participants across both therapy types. Accommodating these preferences is vital, suggesting a clear need to train a diverse range of therapists and guides to enhance patient experience and outcomes.
Abstract
AbstractBackground and AimsResearch on psychedelic-assisted therapy (PAT), a promising treatment option for major depression, has not revealed if p...
[Psilocybin fungi microdose treatment in major depressive disorder: a case report].
Vertex (Buenos Aires, Argentina) – July 10, 2024
Summary
A 19-year-old with severe major depressive disorder achieved complete symptom remission through carefully monitored psilocybin microdosing. Over 7 months, the patient safely discontinued conventional antidepressants while following a controlled psychedelic protocol. Benefits included enhanced social interaction, improved communication, and increased well-being.
Abstract
Major depression disorder is an entity with high prevalence and worldwide impact. Current treatments present a non-response rate of 15-30%, and cer...
Magic of the Mushrooms: Effects of Psilocybin Decriminalization
Journal of Psychoactive Drugs – July 10, 2024
Summary
Decriminalization of psilocybin, a therapeutic hallucinogen, profoundly shifts public interest. Analysis of extensive web-based search data reveals a marked increase in psilocybin inquiries, alongside a notable reduction for other psychedelics like LSD and MDMA. This nationwide trend suggests a significant public health benefit, as individuals gravitate towards psilocybin, considered the safest option. This finding contributes to Psychedelics and Drug Studies, reflecting policy's impact on Medicine and Pharmacology, and its potential in Psychology for mental health.
Abstract
In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in num...
Psilocybin for the treatment of Alzheimer’s disease
Frontiers in Neuroscience – July 10, 2024
Summary
A compelling new medicine for Alzheimer's disease involves psilocybin, a potent hallucinogen and alkaloid from chemical synthesis. Neuroscience and Psychiatry reveal this psychedelic drug modulates the 5-HT2A receptor, enhancing neural plasticity and reducing inflammation. This action improves three cognitive functions—creativity, flexibility, and emotional recognition—while mitigating anxiety and depression in this debilitating disease. Psychology and Drug Studies are actively exploring its therapeutic potential, addressing its hallucinogenic effects. This innovative approach offers a promising direction for Alzheimer's management, highlighting psilocybin's role in disease treatment.
Abstract
Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therap...
Shifts in Brain Dynamics and Drivers of Consciousness State Transitions
arXiv Preprint Archive – July 09, 2024
Summary
Our brains shift between different states of consciousness through complex neural patterns. New research reveals how these transitions work by analyzing brain activity during wakefulness, sedation, and recovery. Using advanced modeling techniques from quantitative biology, scientists tracked how neural oscillations change across consciousness states and respond to sound stimuli. The findings illuminate key drivers of consciousness.
Abstract
Understanding the neural mechanisms underlying the transitions between different states of consciousness is a fundamental challenge in neuroscience...
Effects of Low-Dose Ketamine Infusion on the Positive and Negative Domains of Hopelessness and Suicidal Thoughts.
The Journal of clinical psychiatry – July 08, 2024
Summary
A single low-dose ketamine treatment showed promising results in quickly reducing feelings of hopelessness and suicidal thoughts. In a controlled trial with 84 patients, those receiving ketamine reported significantly improved outlook within 4 hours and reduced negative thoughts by day 2, compared to those given a different medication. The treatment's rapid effect on hopelessness was directly linked to decreased suicidal ideation.
Abstract
Background: Low-dose ketamine infusion has been demonstrated to exert antisuicidal effects on patients with treatment-resistant depression (TRD) an...
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacology bulletin – July 08, 2024
Summary
Mental health treatment is evolving rapidly, with several groundbreaking medications showing promise. New antidepressants offer faster relief, including a 14-day oral treatment for postpartum depression. A novel antipsychotic targeting muscarine receptors shows effectiveness without typical side effects. Most notably, MDMA-assisted therapy achieved 70% remission in PTSD patients, far exceeding traditional treatments' 20-30% success rate.
Abstract
Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year...
Yoga as a Contemplative Practice and Its Contribution to Participatory Self-Knowledge and Student Retention: A Scoping Review of the First-Year Undergraduate Student Transition.
International journal of environmental research and public health – July 07, 2024
Summary
No Summary
Abstract
Contemplative pedagogy, specifically yoga, introduced into the higher education curriculum has the potential to develop and entrain intellectual, e...
A lasting impact of serotonergic psychedelics on visual processing and behavior
OpenAlex – July 06, 2024
Summary
Psilocybin and other Serotonergic psychedelics can yield therapeutic effects lasting weeks, profoundly shifting perception. This Neuroscience and Psychology research, part of Psychedelics and Drug Studies, reveals how these Hallucinogens alter the Sensory system. People using 5-HT2A-agonist psychedelics showed slowed responses to a visual Stimulus and increased visual cortex involvement. Mice exhibited altered visual cortex activity, indicating a shift from top-down to bottom-up processing. This Neurotransmitter Receptor Influence on Behavior, explored via Biochemical Analysis and Sensing Techniques, persists.
Abstract
Abstract Serotonergic psychedelics (e.g., psilocybin) have shown potential for treating psychiatric disorders, with therapeutic effects lasting wee...
Intravenous ketamine for emergency department treatment of suicidal ideation in a paediatric population: protocol for a double-blind, randomised, placebo-controlled, parallel-arm pilot trial (KSI study).
BMJ open – July 05, 2024
Summary
As youth suicide rates rise, emergency departments seek better solutions for immediate crisis care. This pioneering protocol explores ketamine's potential as a rapid treatment for suicidal thoughts in young patients. The hospital-based study will test a single IV dose against placebo in pediatric emergency cases, measuring changes in suicidal ideation over 7 days. This could transform how we help children in mental health emergencies.
Abstract
Suicidal ideation (SI) is a common and severe cause of morbidity in adolescents. Patients frequently present to the emergency department (ED) for c...
Effects of perioperative application of esketamine on postpartum depression in cesarean section: A systematic review and meta-analysis.
Medicine – July 05, 2024
Summary
A promising breakthrough in maternal health: Esketamine during C-sections cuts the risk of postpartum depression by nearly half. Analysis of 1,655 women found that those receiving esketamine during cesarean delivery showed significantly lower depression scores. While the treatment caused temporary side effects like nausea and dizziness, it had no lasting adverse effects and proved effective in protecting maternal mental health.
Abstract
To evaluate the effect of perioperative esketamine administration on postpartum depression in pregnant women undergoing cesarean section. Data sour...
The role of ayahuasca in cell viability and oxidative stress in gastric adenocarcinoma cell line.
Natural product research – July 04, 2024
Summary
Ayahuasca, the ancient Amazonian ceremonial brew, shows promising potential in fighting stomach cancer cells. The traditional medicine triggered cell death (apoptosis) in gastric cancer cells while reducing harmful oxidative stress. Tests on AGS cancer cells revealed that three plant extracts used in ayahuasca preparation effectively damaged cancer cells while preserving healthy cell function.
Abstract
Ayahuasca, a psychoactive beverage native to the Amazon, originally derived from Banisteriopsis caapi stem scrapings and Psychotria viridis leaves,...
Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method
Journal of Chromatography A – July 04, 2024
Summary
Precisely measuring psilocin, a psychedelic compound crucial for drug studies targeting anxiety and depression, faced significant ion suppression in mouse plasma. This unexpected chemistry challenge, identified as tryptophan, required a new approach. A novel liquid chromatography–mass spectrometry method, employing hydrophilic interaction chromatography with electrospray ionization and selected reaction monitoring, was developed. This high-performance liquid chromatography–tandem mass spectrometry technique achieved a 0.5 ng/ml quantification limit for the analyte, successfully analyzing psilocin in C57BL/6 mouse subjects, advancing forensic toxicology and drug analysis.
Abstract
Psilocybin is a psychedelic compound found in some hallucinogenic "magic mushrooms". Psilocin is the active metabolite of Psilocybin, and it is the...
Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence
Current Psychopharmacologye – July 04, 2024
Summary
Psilocybin, a potent hallucinogen, holds significant promise in psychology and psychiatry, sparking interest for substance use disorders. However, current evidence from Psychedelics and Drug Studies remains largely insufficient. Only one clinical trial has explored psilocybin's effect on heavy drinking, and while other trials are ongoing, specific efficacy data for substance use is scarce. Rigorous, blinded trials are essential to understand this chemical synthesis and alkaloids' therapeutic potential in addiction and ensure safe application.
Abstract
Background: Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest...
Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.
Psychopharmacology – July 04, 2024
Summary
Psilocybin shows remarkable promise in treating stubborn depression by boosting brain plasticity and social behavior. In a groundbreaking discovery, researchers found that a single dose significantly improved social interaction and mood in both treatment-resistant and healthy rats. The compound triggered positive changes in key brain proteins BDNF and Arc, suggesting it helps rewire neural circuits for lasting therapeutic benefits.
Abstract
Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (T...
Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey.
Journal of psychoactive drugs – July 03, 2024
Summary
No Summary
Abstract
Treating cannabis use disorder remains a significant challenge in the field of addiction medicine. Some recent studies point to psychedelic-assiste...
Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
Trials – July 03, 2024
Summary
Psilocybin, the active compound in psychedelic mushrooms, shows promise in treating major depressive disorder. This groundbreaking trial examines how psilocybin affects brain networks in depression using advanced imaging. Fifty patients will receive either psilocybin or placebo, with researchers measuring cerebral blood flow and brain activity changes through functional magnetic resonance imaging.
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of lif...
Chronic Neuropathic Pain and Comorbid Depression Syndrome: From Neural Circuit Mechanisms to Treatment.
ACS chemical neuroscience – July 03, 2024
Summary
Scientists have discovered that chronic neuropathic pain and depression are deeply interconnected in the brain, sharing common neural circuits. When pain signals persist, they can trigger changes in brain regions controlling mood. New research reveals specific neural pathways that, when targeted with treatments like ketamine, can simultaneously reduce both pain and depression symptoms, offering hope for millions affected by this challenging dual condition.
Abstract
Chronic neuropathic pain and comorbid depression syndrome (CDS) is a major worldwide health problem that affects the quality of life of patients an...
Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review
Psychoactives – July 03, 2024
Summary
Psilocybin, a hallucinogen, may offer a surprising protective effect against suicidal behavior, a key finding for clinical psychology and psychiatry. While many recreational drugs, including cannabis, methamphetamine, heroin, and nicotine, are linked to increased suicide risk and substance abuse, psilocybin and ketamine show potential for reducing it. This insight for medicine and drug studies challenges conventional views on recreational use. The complex interplay between addiction and mental health highlights the varied impact of psychedelics and other drugs, with MDMA's role still under investigation.
Abstract
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the pre...
Effect of esketamine combined with dexmedetomidine on delirium in sedation for mechanically ventilated ICU patients: protocol for a nested substudy within a randomized controlled trial.
Trials – July 02, 2024
Summary
ICU patients on ventilators face a challenging paradox: the sedatives they need often increase delirium risk. A promising trial explores how combining esketamine with dexmedetomidine in intensive care units could better manage sedation while reducing delirium in patients requiring artificial respiration. This randomized controlled trial will track 134 patients to determine if this combination offers superior outcomes vs. traditional approaches.
Abstract
Use of sedatives and analgesics is associated with the occurrence of delirium in critically ill patients receiving mechanical ventilation. Dexmedet...
Disability rights and experiential use of psychedelics in clinical research and practice.
Npj mental health research – July 02, 2024
Summary
No Summary
Abstract
Given the renewed interest in the use of psychedelics for the treatment of mental and substance use disorders in recent decades, there has also bee...
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
Npj Ment Health Res – July 02, 2024
Summary
Psychedelic therapy has evolved from counterculture to mainstream medicine, with remarkable success in treating mental health conditions. Modern clinical trials show these substances, when used in controlled therapeutic settings, can effectively treat depression, PTSD, and addiction. Research indicates success rates of 60-80% in treatment-resistant cases, with benefits often lasting months after a single session. Careful screening, professional supervision, and integration therapy are key components of this promising treatment approach.
Abstract
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats.
Psychopharmacology – July 01, 2024
Summary
New research reveals that blocking specific brain receptors can enhance ketamine's antidepressant effects. Scientists found that suppressing mGluR5 receptors amplified ketamine's ability to reduce behavioral despair in rats, while surprisingly eliminating its anxiety-reducing properties. Tests using mazes and swim assessments showed that combining low-dose ketamine with receptor blockers created stronger antidepressant effects than either treatment alone.
Abstract
Ketamine produces dissociative, psychomimetic, anxiolytic, antidepressant, and anesthetic effects in a dose dependent manner. It has a complex mech...
Tags
Use of Early Ketamine Sedation and Association With Clinical and Cost Outcomes Among Mechanically Ventilated Patients With COVID-19: A Retrospective Cohort Study.
Critical care explorations – July 01, 2024
Summary
Early ketamine treatment for COVID-19 patients on ventilators may have unexpected drawbacks. In a study of over 42,000 ventilated COVID patients across 610 US hospitals, those receiving ketamine showed higher mortality rates (52.5% vs 45.9%) and longer ICU stays. Treatment also led to increased hospital costs and longer time on ventilators, challenging assumptions about ketamine's benefits in critical care.
Abstract
To describe the utilization of early ketamine use among patients mechanically ventilated for COVID-19, and examine associations with in-hospital mo...
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.
Journal of affective disorders – July 01, 2024
Summary
For every 3 people with difficult-to-treat depression, one person responds positively to ketamine treatment within a week. This groundbreaking analysis of over 2,000 patients reveals both ketamine and esketamine's remarkable efficacy against treatment-resistant depression. The number needed to treat (NNT) shows ketamine works quickly, with benefits appearing within hours and lasting weeks. While traditional antidepressants often fall short, these treatments offer new hope with minimal risks.
Abstract
Ketamine has been established as efficacious in adults living with Treatment-resistant Depression (TRD). Toward providing a quantifiable estimate o...
Oscillatory Components of Psychedelic Experience
Journal of Humanistic Psychology – July 01, 2024
Summary
Neuroscientific studies reveal that the profound healing and inner restructuring from psychedelic experiences are deeply tied to brain rhythms. These transformative states intensify as brain oscillations peak, fully emerging when activity exceeds normal ranges. Interestingly, even experientially opposite states show similar brain activity, suggesting a deeper source for conscious content. This dynamic interplay offers significant therapeutic potential.
Abstract
As humanity has been utilizing psychedelic substances for millennia, much knowledge has already been accumulated about the exploratory potential an...
Environmental enrichment enhances the antidepressant effect of ketamine and ameliorates spatial memory deficits in adult rats.
Pharmacology, biochemistry, and behavior – July 01, 2024
Summary
Enriched environments combined with ketamine show promising results in fighting depression. When rats were given ketamine while living in stimulating environments with toys and social interaction, they showed significantly reduced behavioral despair and improved spatial memory compared to those in standard cages. The treatment activated specific brain regions, including the habenula, and increased C-Fos protein levels, indicating enhanced neural activity. This breakthrough suggests that enriched environments can boost ketamine's antidepressant effects while minimizing side effects.
Abstract
Ketamine is a rapid-acting antidepressant associated with various cognitive side effects. To mitigate these side effects while enhancing efficacy, ...
Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.
Psychopharmacology – July 01, 2024
Summary
Combining Deep TMS therapy with ketamine infusions shows promising results for treating Major Depressive Disorder, with response rates over 80%. This innovative approach pairs brain stimulation with targeted medication to help patients who haven't responded to conventional treatments. Both combined and TMS-only treatments significantly reduced depression symptoms, with similar success rates between groups.
Abstract
Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-...
Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Journal of affective disorders – July 01, 2024
Summary
Breakthrough research reveals that lower doses of ketamine may be just as effective in treating major depressive disorder. Clinical trials show both intravenous ketamine and intranasal esketamine significantly reduce depression symptoms, with dose escalation studies finding optimal results at moderate levels. Higher doses didn't provide additional benefits, suggesting a "sweet spot" for treatment effectiveness.
Abstract
Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (...
Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders.
Discover mental health – July 01, 2024
Summary
While ketamine shows promise as a rapid-acting antidepressant, careful monitoring is essential. Analysis of patient data reveals that ketamine treatment for major depressive disorder can be highly effective when properly administered, but clinicians now have better tools to screen for potential misuse. A new standardized assessment protocol helps doctors safely deliver this breakthrough therapy while minimizing abuse risks.
Abstract
Ketamine, a pharmacological agent that acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, has garnered considerable interest becaus...
Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.
The Australian and New Zealand journal of psychiatry – July 01, 2024
Summary
A groundbreaking public hospital program in Australia has made ketamine treatment accessible to patients with severe depression who couldn't afford private care. The initiative demonstrated successful implementation of ketamine therapy in a public healthcare setting, helping patients who hadn't responded to traditional treatments. The program established protocols, safety measures, and delivery methods that other public hospitals can now replicate, marking a significant step toward making innovative mental health treatments available to all.
Abstract
One could argue that we are living through a period of innovation and change in psychiatry unlike that seen before, with repurposed medications eme...
Centering and flourishing: an online intervention study assessing the effects of a Christian contemplative practice on stress-reduction and human flourishing.
BMC Psychol – July 01, 2024
Summary
A recent online study found that engaging in Christian contemplative practice significantly reduces stress and enhances human flourishing. Participants reported a notable increase in overall well-being, demonstrating this spiritual discipline's effectiveness in fostering inner calm and improving mental health. This shows a clear path to greater peace.
Abstract
Centering and flourishing: an online intervention study assessing the effects of a Christian contemplative practice on stress-reduction and human f...
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
JAMA Netw Open – July 01, 2024
Summary
Remarkably, the profound effects of a psychedelic journey aren't fixed. Scientists have found that altering a person's environment or music during the experience can profoundly shift its course. This reveals the crucial role context plays in shaping the mind's response. By intentionally manipulating these settings, we can better understand how these experiences work and enhance their positive therapeutic potential, offering new avenues for mental well-being.
Abstract
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Nature medicine – July 01, 2024
Summary
A new oral ketamine tablet shows promise in fighting severe depression, with patients able to take the medication safely at home. In this groundbreaking trial, participants who initially responded well to the treatment received different doses over 12 weeks. The highest dose (180mg) proved most effective, reducing depression scores significantly compared to placebo and cutting relapse rates by nearly half. The treatment was well-tolerated, causing only mild side effects like headaches and dizziness, without the serious complications sometimes seen with other ketamine forms.
Abstract
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemi...
Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety.
Journal of psychiatric research – July 01, 2024
Summary
Groundbreaking treatments offer new hope for those battling severe depression. A comprehensive network meta-analysis reveals that both electroconvulsive therapy and ketamine significantly improve symptoms, with ECT showing the strongest results. When comparing these treatments across multiple studies involving 1,370 patients, ECT emerged as the most effective option, followed by combined ECT-ketamine therapy, and ketamine alone.
Abstract
Ketamine, electroconvulsive therapy (ECT), and their combination are effective for treating severe depression, but few large-scale studies have com...
Ketamine intolerance in patients on enhanced recovery after surgery protocols undergoing colorectal operations.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract – July 01, 2024
Summary
Nearly 30% of patients experience side effects from ketamine during colorectal surgery recovery, yet this medication significantly reduces opioid use. Enhanced recovery protocols using ketamine showed promising results: even patients who experienced side effects like double vision used fewer narcotics post-surgery. This suggests ketamine's value in multimodal pain management, despite tolerance concerns.
Abstract
Ketamine is used in enhanced recovery after surgery (ERAS) protocols because of its beneficial antihyperalgesic and antitolerance effects. However,...
Qualitative transformations of street-seized ecstasy over a decade: A case study in Rio de Janeiro (Brazil).
Journal of forensic sciences – July 01, 2024
Summary
Brazilian ecstasy tablets underwent dramatic changes over a decade, with chemical profiling revealing a complex mix of substances. Analysis of seized drugs showed MDMA being increasingly cut with substances like caffeine and clobenzorex. Major events in Rio affected drug composition patterns, while highway-linked samples suggested targeted distribution to truck drivers.
Abstract
The illegal drug market is constantly evolving, with new drugs being created and existing ones being modified. Adulterants are often added to the m...
Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.
Psychiatry research – July 01, 2024
Summary
A breakthrough in mental health treatment shows that small doses of ketamine injected under the skin can rapidly reduce suicidal thoughts and depression. In this groundbreaking approach, patients received carefully monitored doses, with most showing significant improvement after eight sessions. The C-SSRS assessment tool confirmed dramatic decreases in suicidal ideation, while depression symptoms notably improved. This well-tolerated treatment could offer new hope for those battling severe depression and thoughts of suicide.
Abstract
This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial ne...
Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
Focus (American Psychiatric Publishing) – July 01, 2024
Summary
Psychedelic compounds like psilocybin show promise in treating anorexia nervosa by targeting serotonin pathways and improving cognitive flexibility. Research using animal models reveals that these substances may help break rigid eating patterns by activating specific brain receptors. Studies combining behavioral therapy with carefully monitored psychedelic medicine could offer new hope for this challenging condition.
Abstract
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective d...
Fixed dose ketamine for prehospital management of hyperactive delirium with severe agitation.
The American journal of emergency medicine – July 01, 2024
Summary
Fixed-dose ketamine proves effective in prehospital care for managing hyperactive delirium. A 250mg dose successfully calmed 80% of severely agitated patients, with minimal complications. While traditional sedation relies on weight-based dosing, this standardized approach simplified treatment for emergency responders while maintaining safety. Most patients recovered well, with all surviving to hospital discharge.
Abstract
Patients exhibiting signs of hyperactive delirium with severe agitation (HDSA) may require sedating medications for stabilization and safe transpor...
Comparison of propofol-esketamine versus propofol-sufentanil for deep sedation and analgesia in children with autism: A randomized double-blind clinical trial.
Autism research : official journal of the International Society for Autism Research – July 01, 2024
Summary
Children with autism receiving esketamine with propofol during colonoscopy procedures showed better outcomes than those given sufentanil combinations. The esketamine group experienced fewer adverse reactions, more stable blood pressure, and less movement during procedures. This safer approach to anesthesia could benefit many autistic children needing medical procedures.
Abstract
Propofol sedation, routinely used for endoscopic procedures, is safe and acceptable for children. Adjuvants, such as esketamine or sufentanil, are ...
Subanesthetic S-ketamine does not acutely alter striatal dopamine transporter binding in healthy Sprague Dawley female rats.
Synapse (New York, N.Y.) – July 01, 2024
Summary
S-ketamine, a promising fast-acting antidepressant, may work differently than scientists thought. New research using advanced brain imaging (PET) found that single doses don't affect dopamine transporter levels in the brain's reward center. This challenges previous theories about how this rapid-acting treatment lifts depression, suggesting its effectiveness likely stems from other neurological mechanisms.
Abstract
Major depressive disorder is one of the most prevalent mental health disorders, posing a global socioeconomic burden. Conventional antidepressant t...
Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.
Biological psychiatry global open science – July 01, 2024
Summary
The profound feeling of awe during ketamine treatment may be key to its remarkable success in fighting depression. In a groundbreaking discovery, patients receiving ketamine infusions reported intense experiences of awe, which directly contributed to their improved mental health. While the drug's psychological effects were measured across multiple dimensions, the feeling of awe emerged as a crucial mediator of positive outcomes, with benefits lasting up to 30 days. Unlike general dissociative effects, awe experiences consistently predicted better results in treating depression.
Abstract
Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms...
Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis.
Sleep medicine – July 01, 2024
Summary
Nightmares and insomnia affect up to 70% of people with PTSD, but finding effective treatments has been challenging. A comprehensive analysis of nearly 100 clinical trials, involving over 10,000 participants, reveals that prazosin shows the most promise in improving sleep quality and reducing nightmares in PTSD patients. Surprisingly, commonly prescribed medications like antidepressants and sleeping pills showed limited effectiveness. The findings suggest a need to reconsider current treatment approaches, as some widely-used medications may cause drowsiness without meaningful benefits.
Abstract
Sleep disturbances are an important symptom dimension of post-traumatic-stress-disorder (PTSD). There is no meta-analytic evidence examining the ef...
Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.
Psychiatry research – July 01, 2024
Summary
A promising depression treatment combining ketamine with glutathione shows how fighting inflammation may help mood disorders. While ketamine alone helps treatment-resistant depression by promoting neuroplasticity, adding the antioxidant glutathione aimed to reduce oxidative stress that often accompanies major depressive disorder. In a 30-person trial, both approaches significantly improved symptoms for two weeks post-treatment.
Abstract
Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD). Recent studies have shown that there are incr...